Inhibrx Biosciences, Inc. (INBX)
US — Healthcare Sector
Automate Your Wheel Strategy on INBX
With Tiblio's Option Bot, you can configure your own wheel strategy including INBX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INBX
- Rev/Share 0.0129
- Book/Share 6.1057
- PB 2.4911
- Debt/Equity 0.0834
- CurrentRatio 5.119
- ROIC -1.4953
- MktCap 220178500.0
- FreeCF/Share -10.9098
- PFCF -1.3047
- PE 0.1365
- Debt/Assets 0.0325
- DivYield 0
- ROE 11.0119
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Inhibrx Biosciences, Inc. (INBX)
- IPO Date 2024-06-04
- Website https://inhibrx.com
- Industry Biotechnology
- CEO Mr. Mark Paul Lappe
- Employees 156
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.